secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001171843-25-007293
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose reports Q3 net loss $5.1M, cash $1.6M, but TUS+VEN+AZA shows 100% CR/CRh at higher doses
--------------------------------------------------------------------------------

- Net loss $5.1M (-$2.01/share) for Q3 2025 vs $7.0M (-$11.33/share) in Q3 2024; nine-month net loss $17.7M.
- Cash and equivalents $1.6M as of Sep 30, 2025; company states insufficient cash to fund operations, relying on Hanmi advances.
- TUS+VEN+AZA triplet: 6/6 (100%) achieved CR/CRh at 80/120 mg TUS doses, exceeding 66% expected from VEN+AZA alone; overall 9/10 (90%) CR/CRh.
- Dose escalation to 160 mg TUS underway; updated data to be presented at ASH December 2025.
- Shareholders' deficit of $19.5M; company actively pursuing financing and cost reductions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325007293/0001171843-25-007293-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325007293/f8k_111325.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007293

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer